Tag Archives: JBS2
December 2013 Br J Cardiol 2013;20(suppl 3):S1–S19 doi:10.5837/bjc.2013.s05
Dyslipidaemia and atherosclerotic vascular disease: DYSIS results in the UK
Vian Amber, Kornelia Kotseva, Elizabeth L Turner, Catriona Jennings, Alison Atrey, Jennifer Jones, Susan Connolly, Timothy J Bowker, David A Wood, on behalf of the DYSIS Study Group UK
Background Statins are first choice for treatment of dyslipidaemia in both secondary and primary cardiovascular disease prevention. For every 1.0 mmol/L reduction in low-density lipoprotein cholesterol (LDL‑C), the risk of coronary heart disease (CHD) mortality decreases by 19% and overall mortality decreases by 12%.1 Despite statin treatment, a substantial number of cardiovascular events still occur, and one reason may be persistent lipid abnormalities including total cholesterol and LDL-C not at target, or low levels of high-density lipoprotein cholesterol (HDL-C) or elevated triglycerides. Results from the DYSlipidaemia International Stu
For healthcare professionals only
